Based on the lack of systemic exposure and negligible biodistribution to the gonads, the risk for germline transmission is low.
There are no data from the use of eladocagene exuparvovec in pregnant women. Animal reproductive studies have not been conducted with eladocagene exuparvovec.
It is unknown whether eladocagene exuparvovec is excreted in human milk.
Eladocagene exuparvovec is not absorbed systemically following intraputaminal administration, and no effect on the breastfed newborns/infants are anticipated.
There are no clinical or nonclinical data available regarding the effect of eladocagene exuparvovec on fertility.
Not relevant.
The safety information was observed in 3 open-label clinical studies in which eladocagene exuparvovec was administered to 28 AADC-deficient patients aged 19 months to 8.5 years at the time of dosing. Patients were followed for a median duration of 52.3 months (minimum of 3.1 months to a maximum of 9.63 years). The most common adverse reaction was dyskinesia; it was reported in 24 (85.7%) patients and was prevalent during the first 2 months post-treatment.
The adverse reactions are reported in Table 1. The adverse reactions are listed by system organ class and frequency using the following convention: very common (≥1/10), common ≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Table 1. Adverse reactions occurring in ≥2 patients in 3 open-label clinical studies (n=28):
System organ class | Very common | Common |
---|---|---|
Psychiatric disorders | Initial insomnia, irritability | |
Nervous system disorders | Dyskinesia | |
Gastrointestinal disorders | Salivary hypersecretion |
Table 2. Neurosurgery-related adverse reactions occurring in ≥2 patients in 3 open-label clinical studies (n=28):
Adverse reaction category | Very common |
---|---|
Blood and lymphatic system disorders | Anaemia |
Nervous system disorders | Cerebrospinal fluid leakagea |
a May include pseudomeningocele
Table 3. Anaesthesia and postoperative related adverse reactions in ≥2 patients within ≤2 weeks after administration, in 3 open label clinical studies (n=28):
Adverse reaction category | Very common | Common |
---|---|---|
Infections and infestations | Pneumonia | Gastroenteritis |
Metabolism and nutrition disorders | Hypokalaemia | |
Psychiatric disorders | Irritability | |
Nervous system disorders | Dyskinesia | |
Cardiac disorders | Cyanosis | |
Vascular disorders | Hypotension | Hypovolemic shock |
Respiratory, thoracic and mediastinal disorders | Respiratory failure | |
Gastrointestinal disorders | Upper gastrointestinal haemorrhage, Diarrhoea | Mouth ulceration |
Skin and subcutaneous tissue disorders | Decubitus ulcer, Dermatitis diaper, Rash | |
General disorders and administration site conditions | Pyrexia Breath sounds abnormal | Hypothermia |
Surgical and medical procedure | Tooth extraction |
Events of dyskinesia were reported in 24 (85.7%) subjects. Of the 35 events of dyskinesia, 33 events were mild to moderate and 2 were severe. The majority of events resolved in approximately 2 months and all resolved within 7 months. The mean time to onset of events of dyskinesia was 25.8 days after receiving gene therapy. Events of dyskinesia were managed with routine medical care, such as anti-dopaminergic treatment.
Titres of anti-AAV2 antibodies were measured pre- and post-gene therapy in the clinical studies. All patients that received eladocagene exuparvovec had anti-AAV2 titres at or below 1:20 before treatment. Following treatment, most subjects (n=18) were positive for anti-AAV2 antibodies at least once within the first 12 months. In general, antibody levels stabilised or declined with time. There was no specific follow up program to capture potential immunogenicity reactions in any of the clinical studies, but presence of anti-AAV2 antibodies in the clinical studies was not reported to be associated with increase in severity, number of adverse reactions, or with decreased efficacy.
Experience with eladocagene exuparvovec in patients with anti-AAV2 antibody levels >1:20 prior to treatment is not available.
The immune response to the transgene and the cellular immune response were not measured.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.